New York

Florida Eye Doctor Tied to Menendez Profited by Fraud, False Hopes, Prosecutor Says in Medicare Fraud Trial

What to Know

  • Prosecutors allege Florida ophthalmologist Salomon Melgen stole millions from Medicare between 2004 and 2013
  • Melgen has pleaded not guilty to fraud, and separately, to bribing U.S. Sen. Bob Menendez
  • The 62-year-old doctor faces up to 610 years in prison if convicted in the fraud case

A prominent Florida eye doctor tied to a U.S. senator's alleged corruption built much of his fortune by defrauding Medicare and instilling false hopes in his patients, a federal prosecutor told a jury Thursday. 

Salomon Melgen stole millions from Medicare between 2008 and 2013 by falsely diagnosing patients and by performing unnecessary tests and treatments, Assistant U.S. Attorney Carolyn Bell said during her opening statement for Melgen's fraud trial. Melgen and Democratic New Jersey Sen. Bob Menendez face a separate trial in the fall in an alleged bribery case. 

"This is a case about a doctor who lied to Medicare for money," Bell told the 12-member panel. He lied about his patients' diagnoses, she said. He lied about the tests he ran, she said. He lied about their prognoses, she said. All of it, she said, aimed at making Melgen rich, as many of these falsely diagnosed and treated patients could net him $72,000 each annually. 

Medicare paid Melgen because it "relied on the integrity of the doctor," she said, but the government's investigation found that in many cases he "lied," using that word or a variation about two dozen times. 

Matthew Menchel, Melgin's attorney, countered during his opening that the government's case is built upon viewing Melgen's actions as criminal when they were actually aggressive medicine, legitimate differences of opinions between doctors and honest mistakes. 

"There is an old saying that when you look at the world through a dirty window, everything looks dirty," Menchel told the jury, saying that mindset gave prosecutors "a twisted interpretation" of the evidence. It led prosecutors, he said, to ignore facts that support Melgen's innocence. 

"They turned a blind eye to evidence they didn't like," he said. 

Many charges relate to patients Melgen said had age-related macular degeneration, one of the leading causes of severe vision loss in people 65 and older. Most ARMD patients have the "dry" variety, which is caused by retinal cells breaking down and cannot be treated. Fewer have the "wet" variety, which involves bleeding beneath the retina. It can be treated by injections. 

Prosecutors say Melgen falsely diagnosed many patients with ARMD so he could run unneeded tests. They say he also falsely claimed patients with dry ARMD had wet ARMD, giving them multiple injections that had no benefit. 

Bell displayed photographs of several Melgen patients' that she said were used without their knowledge to defraud Medicare. Patients, she said, whose prosthetic eye Melgen claimed on multiple occasions to have tested and treated. Patients, she said, who had untreatable dry ARMD but Melgen put them through useless, sometimes painful but always profitable tests and treatments. Patients, she said, who were told that if they kept visiting Melgen, they would get better when there was no hope that was true. 

"This highly trained, Harvard and Yale educated specialist would falsely diagnose patients to justify injecting eyes that did not need it and lied to Medicare about it," Bell said. 

Menchel said other doctors who have looked at Melgen's diagnoses and treatments don't always agree with him, but say they understand what he was attempting. Other eye doctors sent Melgen their hardest, most desperate patients because they knew of his "cutting edge" treatments that sometimes worked, Menchel said. 

"Many of Dr. Melgen's patients loved him, not just liked him, because he helped them," Menchel said. 

If convicted on the Medicare fraud counts, Melgen faces up to 610 years in prison. He is free on $18 million bond. The trial is expected to last about six weeks.

Copyright AP - Associated Press
Contact Us